J&J drops out of RSV vaccine race with Pfizer and GSK.
TL;DR Summary
Johnson & Johnson has ended development of its adult RSV vaccine in the middle of a 27,200-patient trial, citing a shifting competitive landscape. Emergent BioSolutions' Narcan brand naloxone nasal spray has been approved by the FDA for over-the-counter sales. AstraZeneca has scrapped its license agreement with Aridis Pharmaceuticals, putting a European-funded Phase III trial on hold.
Topics:business#astrazeneca#emergent-biosolutions#johnson-and-johnson#narcan#pharmaceuticals#rsv-vaccine
- J&J bows out of RSV vaccine race, ending PhIII study and ceding to Pfizer, GSK Endpoints News
- J&J backs out of RSV vaccine race with rivals Pfizer and GSK CNBC
- J&J bows out of RSV vaccine race after scrapping trial Reuters
- Janssen Provides Portfolio Update PR Newswire
- J&J scraps late-stage RSV vaccine in R&D overhaul, dropping out of race with GSK, Pfizer FierceBiotech
Reading Insights
Total Reads
0
Unique Readers
10
Time Saved
6 min
vs 7 min read
Condensed
96%
1,261 → 56 words
Want the full story? Read the original article
Read on Endpoints News